U.S. markets closed
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow 30

    31,500.68
    +823.32 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.43 (+3.34%)
     
  • Russell 2000

    1,765.74
    +54.06 (+3.16%)
     
  • Crude Oil

    107.06
    +2.79 (+2.68%)
     
  • Gold

    1,828.10
    -1.70 (-0.09%)
     
  • Silver

    21.13
    +0.09 (+0.42%)
     
  • EUR/USD

    1.0559
    +0.0034 (+0.33%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.07%)
     
  • USD/JPY

    135.2100
    +0.2770 (+0.21%)
     
  • BTC-USD

    21,210.10
    +288.27 (+1.38%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,491.97
    +320.72 (+1.23%)
     

Kodiak Sciences' KSI-301 Shows Durable Benefit In Retinal Disease Settings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Kodiak Sciences Inc (NASDAQ: KODannounced new data from one-year durability, efficacy, and safety data from the ongoing Phase 1b study evaluating KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degeneration (wet AMD) diabetic macular edema (DME) and retinal vein occlusion (RVO).

  • Kodiak presented the data at the Angiogenesis, Exudation, and Degeneration 2021 Annual Meeting.

  • Data showed that two-thirds of patients in each disease cohort achieved a 6-month or longer treatment-free interval at the one-year mark – 66% of wet AMD patients, 69% of DME patients, and 66% of RVO patients.

  • 78% of wet AMD patients and 84% of DME patients were on a 4-month or longer interval at Year 1, as were 75% of RVO patients. 54% of wet AMD patients required only one retreatment, and 50% of DME patients required no retreatment in Year 1.

  • The DAZZLE wet AMD study is fully recruited with an expected data read-out in early 2022, and GLEAM and GLIMMER studies in DME and BEACON study in RVO are actively recruiting.

  • Price Action: KOD stock closed 2.2% down at $157.03 on Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.